305 related articles for article (PubMed ID: 17456615)
1. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
4. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
5. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
8. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
9. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
10. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Sparacino V; Calabrese S
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients.
Fryer AA; Ramsay HM; Lovatt TJ; Jones PW; Hawley CM; Nicol DL; Strange RC; Harden PN
Carcinogenesis; 2005 Jan; 26(1):185-91. PubMed ID: 15459020
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
14. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
Audard V
Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia.
Carroll RP; Ramsay HM; Fryer AA; Hawley CM; Nicol DL; Harden PN
Am J Kidney Dis; 2003 Mar; 41(3):676-83. PubMed ID: 12612993
[TBL] [Abstract][Full Text] [Related]
16. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study.
Tessari G; Naldi L; Boschiero L; Nacchia F; Fior F; Forni A; Rugiu C; Faggian G; Sassi F; Gotti E; Fiocchi R; Talamini G; Girolomoni G
Arch Dermatol; 2010 Mar; 146(3):294-9. PubMed ID: 20231501
[TBL] [Abstract][Full Text] [Related]
18. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers.
Veness MJ; Harris D
Australas Radiol; 2007 Feb; 51(1):12-20. PubMed ID: 17217484
[TBL] [Abstract][Full Text] [Related]
19. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
Ruiz JC; Sanchez-Fructuoso A; Rodrigo E; Conesa J; Cotorruelo JG; Gómez-Alamillo C; Calvo N; Barrientos A; Arias M
Transplant Proc; 2006 Oct; 38(8):2424-6. PubMed ID: 17097956
[TBL] [Abstract][Full Text] [Related]
20. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations.
Zavos G; Karidis NP; Tsourouflis G; Bokos J; Diles K; Sotirchos G; Theodoropoulou E; Kostakis A
Int J Dermatol; 2011 Dec; 50(12):1496-500. PubMed ID: 21790552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]